Ò©ÀíѧÂÛÎÄ

Äúµ±Ç°µÄλÖãºÑ§ÊõÌà > ҽѧÂÛÎÄ > »ù´¡Ò½Ñ§ÂÛÎÄ > Ò©ÀíѧÂÛÎÄ >

¹úÄÚÍâÈéҩŨ¶È²â¶¨µÄ·½·¨Ì½Îö

À´Ô´£ºÖйúҽԺҩѧÔÓÖ¾ ×÷ÕߣºÀîÄþºì ÕÔæÃ»Û ÇÇÈï
·¢²¼ÓÚ£º2021-04-13 ¹²16425×Ö

¡¡¡¡Õª    Òª£º¡¡Ä¸ÈéιÑø¶ÔÓ¤¶ùÀ´ËµÊÇÒ»Öַdz£½¡¿µ¼°ÓÐÓªÑøµÄ»ñÈ¡ÄÜÁ¿µÄ·½Ê½£¬¶ÔĸÇ׺ÍÓ¤¶ù¶¼ÓÐÒæ´¦¡£»¼ÓÐijЩ¼²²¡µÄ²¸ÈéĸÇ×ÔÚ½øÐÐÒ©ÎïÖÎÁÆʱ£¬ÐèÒª¿¼ÂÇÒ©ÎïÊÇ·ñ»á½øÈëÈéÖ­¶ø¶ÔÓ¤¶ù²úÉúһЩ²»Á¼·´Ó¦»ò¶ÔĸÇײúÉúÓ°Ïì¡£ÓÉÓÚÐí¶àÒ©ÎïµÄ²¸ÈéÆÚÓÃÒ©°²È«ÐÔ²¢²»Ê®·ÖÃ÷È·£¬Òò´ËÔÚÁÙ´²ÖÎÁÆÖв»ÍƼö²¸È鸾ŮʹÓᣲⶨÈéÖ­ÖеÄÒ©ÎïŨ¶È¿ÉÒÔÃ÷È·ºÏÀíµÄ¸øҩʱ¼äºÍ¸øÒ©¼ÁÁ¿£¬Ìá¸ßÓÃÒ©°²È«ÐÔ£¬¶ÔÁÙ´²ÓÃÒ©¾ßÓзdz£ÖØÒªµÄÒâÒå¡£µ«ÈéÖ­³É·Ö¸´ÔÓ£¬º¬ÓдóÁ¿Ö¬Öʺ͵°°×ÖʵȸÉÈÅÎïÖÊ£¬Ê¹ÈéҩŨ¶È²â¶¨ÓÐÒ»¶¨À§ÄÑ¡£±¾ÎÄ×ÛÊöÁ˹úÄÚÍâÈéҩŨ¶È²â¶¨·½·¨£¬Îª²¸ÈéÆÚºÏÀíÓÃÒ©Ìṩ²Î¿¼¡£

¡¡¡¡¹Ø¼ü´Ê£º¡¡ÈéÖ­; Ò©ÎïŨ¶È; ²â¶¨·½·¨;

¡¡¡¡Abstract£º¡¡Breastfeeding is a quite healthy way for babies to get energy and nutrients, which is beneficial to mothers and infants. When breastfeeding mothers who suffer from certain diseases need to use drugs, it is necessary to consider whether drugs will be excreted into the milk to cause adverse effects on infants or affect lactation. Because the safety of many drugs during lactation is not very clear, many drugs are not recommended for nursing women in clinical treatment. Determination of drug concentration in breast milk can provide reasonable administration time and dose, which is of great significance for clinical medication. However, breast milk is a complicate matrix due to a lot of lipids and proteins and other interfering substances, which poses a challenge for determination of drug concentration in breast milk. The domestic and abroad methods for determination of milk concentration of drugs are reviewed in this article, aiming to provide a reference rational drug use in lactation.

¡¡¡¡Keyword£º¡¡human milk; drug concentration; determination method;

¡¡¡¡Ä¸ÈéιÑø¶ÔÐÂÉú¶ùÀ´ËµÊÇÒ»ÖÖ¼«¼ÑµÄ²¸Óý·½Ê½£¬ÈéÖ­ÖеĶàÖÖÌìȻӪÑøÎïÖÊ¿ÉÒÔÂú×ãÓ¤¶ù×Â׳³É³¤µÄÐèÒª¡£Ä¸ÈéÖк¬ÓеĴóÁ¿ÃâÒßÎïÖÊ»¹¿ÉÒÔÔöÇ¿ÐÂÉú¶ùµÄµÖ¿¹Á¦ºÍÃâÒßÁ¦£¬ÓÐЧԤ·ÀһЩӤ¶ù¼²²¡[1]¡£Ä¸ÈéιÑø»¹¿ÉÒÔ½µµÍĸÇ×»¼ÈéÏÙ°©µÄ¼¸ÂÊ£¬ÔöǿĸÇ×Ó뺢×ÓÖ®¼äµÄ½»Á÷£¬¶ÔÓ¤¶ùºÍĸÇ׶¼ÓÐÒæ´¦¡£²¸ÈéÆÚÓÃÒ©ÊǺܳ£¼ûµÄ£¬Óе÷²é·¢Ïָߴï96%µÄ²¸È鸾ŮÔÚ²¸Èéʱ»á·þÓÃÒ»ÖÖ»ò¶àÖÖÒ©Îï[2]¡£Òò¼¸ºõËùÓеÄÒ©Îﶼ¿ÉÒÔÔÚÈéÖ­ÖгöÏÖ£¬ÇÒÓ¤¶ùµÄøϵͳ»¹Î´·¢ÓýÍêÈ«£¬Ò©Îï´úлºÍÅÅйÄÜÁ¦²î£¬³ÔÁ˺¬ÓÐÒ»¶¨Ò©ÎïŨ¶ÈµÄĸÈéºóºÜÓпÉÄÜ·¢ÉúһϵÁв»Á¼·´Ó¦¡£Òò¶ø£¬ÓÃÒ©Æڼ䲸Èé±»ÈÏΪÊDz»°²È«µÄ[3]¡£¶ÔÓÚÐèÒª·þÒ©¿ØÖƼ²²¡µÄĸÇ×À´Ëµ£¬ÊÇ·ñ¼ÌÐø²¸Èé³ÉÁËÒ»¸öÄÑÌâ¡£
 

¹úÄÚÍâÈéҩŨ¶È²â¶¨µÄ·½·¨Ì½Îö
 

¡¡¡¡Ä¿Ç°Ðí¶àÒ©Îïȱ·¦²¸È鰲ȫÐÔÊý¾Ý£¬¶ÔÓÚÒ©ÎïÔÚ²¸ÈéÆÚʹÓõÄΣÏÕÐÔ»¹²»ÉõÇå³þ£¬¶Ô²¸ÈéÆÚÒ©ÎïµÄ°²È«ÐÔ·ÖÀàҲûÓÐͳһµÄ±ê×¼£¬²¿·ÖҩƷ˵Ã÷ÊéÖжԲ¸ÈéÆÚ¸¾Å®ÓÃÒ©µÄ˵·¨¶à²»Ã÷È·£¬Õâ¶ÔÁÙ´²Ò½ÉúÖ¸µ¼²¸ÈéÆÚ¸¾Å®µÄ°²È«ÓÃÒ©Ò²Ôì³ÉÁËÀ§ÈÅ¡£

¡¡¡¡Ñо¿·ÖÎöÈéÖ­ÖеÄÒ©ÎïŨ¶È¿ÉÒÔΪҩÎïÔÚÈéÖ­Öеķֲ¼Ìṩֱ½ÓµÄÖ¤¾Ý£¬ÎªÅжÏÈéÖ­ÖеÄÒ©ÎïÊÇ·ñ»á¶ÔÐÂÉú¶ù½¡¿µÔì³ÉÓ°ÏìÌṩ²Î¿¼£»»¹¿ÉÒÔÒÀ¾ÝÒ©ÎïÔÚÈéÖ­ÖеĴúл¶¯Á¦Ñ§Êý¾Ý½øÒ»²½Ã÷È·ºÏÀíµÄ¸øҩʱ¼äºÍ¸øÒ©¼ÁÁ¿£¬¾¡¿ÉÄܵØÌá¸ßÓÃÒ©µÄ°²È«ÐÔ£¬Òò¶ø¾ßÓÐÖØÒªµÄÁÙ´²Ó¦ÓüÛÖµ[4]¡£Ä¿Ç°£¬¹ØÓÚÄòÒº¡¢Ñª½¬¡¢ÍÙÒºµÈÌåÒºÖÐÒ©ÎïŨ¶È²â¶¨µÄ±¨µÀ½Ï¶à£¬¹ØÓÚÒ©ÎïÈé֭Ũ¶È²â¶¨µÄÑо¿½ÏÉÙ¡£±¾ÎÄ×ÛÊöÁ˽üÄêÀ´ÈéÖ­ÖÐÒ©ÎïŨ¶È¼à²âµÄÑо¿½øÕ¹£¬ÒÔÆÚΪÈéҩŨ¶È¼à²âºÍ²¸ÈéÆÚ¸¾Å®ºÏÀíÓÃÒ©Ìṩ²Î¿¼¡£

¡¡¡¡1¡¢ Ò©Îï½øÈëÈéÖ­µÄ»úÖƼ°Ó°ÏìÒòËØ

¡¡¡¡1.1 ¡¢»úÖÆ

¡¡¡¡ÈéÏÙÓÉСҶ-µ¼¹Ü-ÏÙÅݹ¹³É£¬ÈéÖ­´ÓÏÙÅÝÖзÖÃÚ¡£ÏÙÅÝÉÏÅÅÁÐ×ÅÒ»²ãÉÏƤϸ°û£¬ÔÚ³õÈéÆÚ£¨²úºó3~4Ì죩£¬ÈéÏÙÉÏƤϸ°û½ÏС£¬Ï¸°û¼äµÄ¼ä϶ʹµÃÃâÒßÇòµ°°×¡¢µ°°×ÖÊ¡¢Ò©ÎïµÈ´ó·Ö×ÓÎïÖÊÒ×´ÓѪҺ½øÈëÈéÖ­[5]¡£Ëæ×ųõÈéÏò³ÉÊìÈé¹ý¶É£¬ÈéÏÙÅÝÖеÄÈéÏÙÉÏƤϸ°ûÐγÉÒ»²ã°ë͸Ã÷µÄÖ¬ÖÊĤ½«ÈéÖ­ÓëѪ½¬·Ö¸ô¿ª£¬´ËʱÉÏƤϸ°û¼ä¿Õ϶½Ï´ó£¬´ó·Ö×ÓÒ©ÎïÒ×´ÓѪҺ½øÈëÈéÖ­[6]¡£²úºóÒ»Öܺó,ÈéÏÙÉÏƤϸ°û¼äµÄ¿×϶¹Ø±Õ£¬Ö»ÓзÖ×ÓÁ¿Ð¡ÓÚ200µÄÒ©Îï²ÅÄÜͨ¹ý¿×϶½øÈëÈéÖ­£¬´ó·Ö×ÓÒ©Îï±ØÐëͨ¹ý±»¶¯À©É¢²ÅÄÜ͸¹ýÕâ²ãĤ[7,8]¡£

¡¡¡¡1.2 ¡¢Ó°ÏìÒòËØ

¡¡¡¡Á˽âÓ°ÏìÒ©ÎïÔÚĸÈéÖеķֲ¼¡¢´úлºÍÇå³ýÒòËØ£¬¶ÔÓÚÖ¸µ¼±ØÐë·þÓÃÒ©ÎïÖÎÁÆÂýÐÔ¼²²¡µÄ²¸ÈéÆÚ¸¾Å®·Ç³£ÖØÒª¡£Ä¿Ç°ÒÑÖªµÄÓ°ÏìÒ©Îï½øÈëÈéÖ­µÄÒòËØÓУº

¡¡¡¡£¨1£©Ëá¼îÐÔ£ºÈéÖ­Ïà¶ÔÓÚѪ½¬Æ«ÈõËáÐÔ£¬ÈõËáÐÔÒ©ÎïÔÚѪ½¬ÖбÈÈõ¼îÐÔÒ©Îï½ÏÒ×½âÀ룬ÄÑÒÔͨ¹ýѪÈéÆÁÕÏ¡£Ò©ÎïËáÐÔԽС£¬pKa¾ÍÔ½´ó£¬Ô½Ò×ͨ¹ýѪÈéÆÁÕÏ[5]¡£

¡¡¡¡£¨2£©µ°°×½áºÏÂÊ£ºÑª½¬ºÍÈéÖ­Öж¼ÓпÉÒÔÓëÒ©Îï½áºÏµÄµ°°×¡£Ñª½¬ÖÐÓëÒ©Îï½áºÏµÄÖ÷ÒªÊÇ°×µ°°×£»¶øÈéÖ­ÖÐÖ÷ÒªÊÇÀÒµ°°×¡¢ÈéÌúµ°°×£¬ÃâÒßÇòµ°°×µÈµ°°×£¬µ«ÈéÖ­Öеĵ°°×ÓëÒ©ÎïµÄ½áºÏÄÜÁ¦½Ï²î¡£Òò´Ë£¬Ñª½¬µ°°×½áºÏÂÊÔ½¸ßµÄÒ©ÎïÔ½Ò×Áô´æÔÚѪ½¬ÖУ¬½øÈëÈéÖ­µÄÁ¿¾ÍÔ½ÉÙ[9]¡£

¡¡¡¡£¨3£©·Ö×ÓÁ¿£ºµÍ·Ö×ÓÁ¿µÄÖ¬ÈÜÐÔÒ©Îï¿Éͨ¹ý±»¶¯×ªÔ˽øÈëÈéÖ­¡£·Ö×ÓÁ¿Ð¡ÓÚ200µÄË®ÈÜÐÔÒ©Îï¿ÉÖ±½Óͨ¹ýϸ°ûĤÉϵÄĤ¿×½øÈëÈéÖ­£¬¶ø·Ö×ÓÁ¿´óµÄÒ©ÎïÔò²»ÄÜͨ¹ý¼òµ¥À©É¢µÄ·½Ê½½øÈëÈéÖ­[6]¡£

¡¡¡¡£¨4£©Ö¬ÈÜÐÔ£ºÖ¬ÈÜÐԸߵķÇÀë×ÓÐÍÒ©ÎïÒ×ͨ¹ý¸»º¬Ö¬ÖʵÄϸ°û¶øÈÜÓÚĸÈéÖ¬·¾ÖС£ÈéÖ­Ö¬·¾ÔÚ³õÈéÆÚ¡¢¹ý¶ÉÈéÆںͳÉÊìÈéÆڵĺ¬Á¿²»Í¬£¬ÔÚÒ»ÌìÖ®ÄÚÖ¬·¾º¬Á¿Ò²ÊDZ仯µÄ£¬Òò´Ë¸ßÖ¬ÈÜÐÔÒ©ÎïÔÚÈéÖ­ÖеÄÒ©ÎïŨ¶ÈÒ²ÊDZ仯µÄ[5]¡£

¡¡¡¡ÁíÍ⣬ÈéҩŨ¶È»¹Óë°ëË¥ÆÚ¡¢¸øҩʱ¼ä¡¢¸øҩ;¾¶¡¢ÈéÖ­³É·Öº¬Á¿µÈÓйء£ÆäÖУ¬ÈéÖ­³É·ÖÊÇÒ»¸öÊ®·ÖÖØÒªµÄÒòËØ¡£ÒòΪĸÈéÖеĵ°°×ÖÊ¡¢Ö¬·¾µÈ³É·Ö»áÓ°ÏìÒ©Îï½øÈëÈéÖ­£¬¶øÒûʳ¡¢×÷Ï¢¡¢²¸Èéʱ¼ä¼°´ÎÊý¡¢²¸È鷽ʽµÈ¶¼»áÓ°ÏìÈéÖ­³É·ÖµÄº¬Á¿[10,11]¡£Òò´Ë£¬²»Í¬¸öÌåÖ®¼äÈéÖ­³É·Ö´æÔڽϴó²îÒ죬Õâ¸øÈéÖ­ÖÐÒ©ÎïŨ¶È²â¶¨´øÀ´ÁËÐí¶à²»È·¶¨ÐÔ¼°ÌôÕ½¡£

¡¡¡¡2¡¢ ÈéҩŨ¶È¼ì²âÈ¡Ñù¼°ÈéÖ­ÑùÆ·Ç°´¦Àí

¡¡¡¡Ä¸ÈéÊÇÒ»Öֳɷָ´ÔӵĻùÖÊ£¬º¬ÓдóÁ¿Ö¬Öʺ͵°°×ÖÊ¡£µ«ÓÉÓÚÖ¬Öʺ͵°°×ÖÊÔÚ²¸ÈéÆÚÄÚÊDZ仯µÄ£¬»áÓ°ÏìÒ©Îï½øÈëÈéÖ­µÄÁ¿£»Ö¬ÖÊ»¹»áËð»µÓÃÓÚ·ÖÎöµÄÉ«Æ×Öù¡£Òò´Ë£¬ÔڲⶨÈéҩŨ¶Èʱ±ØÐë³ýÈ¥ÕâЩ³É·Ö»òÕß²ÉÓöÔÕâЩÎïÖʲ»Ãô¸ÐµÄ²â¶¨·½·¨¡£

¡¡¡¡2.1 ¡¢È¡Ñù

¡¡¡¡ÈéÖ­¿ÉÒÔͨ¹ýÈ˹¤¼·Ñ¹»òÓÃÎüÈé±ÃÊÕ¼¯¡£¼·Ñ¹µÄƵÂÊ¡¢±ÃµÄÕæ¿ÕѹÁ¦µÈ»áÓ°ÏìÈéÖ­·ÖÃÚµÄÁ¿£¬ÇÒ²»Í¬µÄÈ¡Ñù·½Ê½Ò²¿ÉÄܻᵼÖÂÈéÖ­³É·Öº¬Á¿±ä»¯£¬ÕâЩÒòËض¼»áÓ°ÏìÈéÖ­ÖÐÒ©ÎïµÄº¬Á¿[12]¡£È˹¤¼·Ñ¹µÄ·½Ê½¿ÉÄÜ»á¶ÔĸÇ×Ôì³ÉÉ˺¦£¬Ó°Ïì²úÄÌÁ¿£¬ÇÒÒ×ÒýÆðϸ¾ú¸ÐȾ[13]£»ÀûÓÃÆÕͨÎüÈé±ÃÊÕ¼¯ÈéÖ­¿ÉÄܲ»ÊÇ×î׼ȷµÄ·½·¨[14]£¬µ«ÀûÓõ綯ÎüÈé±ÃÈ¡Ñù¿ÉÒÔÌṩһ¶¨³Ì¶ÈµÄ²ÉÑùÖØÏÖÐÔ¡£Òò´Ë£¬²É¼¯ÈéÖ­Ñù±¾ÒËÑ¡ÔñʹÓõ綯ÎüÈé±Ã¡£ÔÚÈ¡µÃ»¼Õß¼°¼ÒÊôµÄͬÒâºó£¬·Ö±ðÔÚ¸øÒ©ºó0.5¡¢2¡¢4¡¢6¡¢8¡¢12¡¢24 hºóÓÃÎüÈé±Ã²É¼¯¡£Í¨³£ÔÚ³õÈéÆÚ£¨²úºó1~7Ì죩¡¢¹ý¶ÉÈéÆÚ£¨²úºó8~14Ì죩¡¢³ÉÊìÈéÆÚ£¨²úºó14ÌìÒÔÉÏ£©²É¼¯»¼ÕßÈé·¿ÄÚÈ«²¿ÈéÖ­£¬È¡2~5 mL»¼ÕßÈéÖ­ÑùÆ·ÓÚÎÞ¾ú¾Û±ûÏ©¹ÜÖÐ[15,16]¡£È¡ÑùÇ°×¢ÒâÓÃÕôÁóË®ºÍÈ¥Àë×ÓË®ÇåÏ´Ò»ÏÂÈéÍ·£¬ÔÚÈ¡Ñù¹ý³ÌÖо¡Á¿±ÜÃâÎÛȾ¡£

¡¡¡¡2.2¡¢ ÈéÖ­ÑùÆ·Ç°´¦Àí

¡¡¡¡ÈéÖ­Öгɷָ´ÔÓÇÒ¸öÌåÖ®¼ä²îÒì½Ï´ó£¬¸øÈéÖ­ÖÐÒ©ÎïŨ¶È²â¶¨´øÀ´Á˼«´óµÄÌôÕ½[17]¡£ÔÚ½øÑù·ÖÎöʱ£¬ÈéÖ­ÖеĶàÖÖÔÓÖÊ¿ÉÄÜ»á¸ÉÈÅÖ÷Ò©É«Æ×·åµÄ·ÖÎö£¬Ö¬·¾ºÍµ°°×ÖÊ»¹Ò׶ÂÈûÉ«Æ×Öù¡£Òò´Ë£¬ÔÚ½øÑù·ÖÎö֮ǰӦ¾¡¿ÉÄܵØÈ¥³ýÈéÖ­ÖеÄÔÓÖÊ£¬ÓÐЧµÄÈéÖ­ÑùÆ·Ç°´¦Àí·½·¨Ò²ÓÐÖúÓÚÌá¸ß¼ì²â·½·¨µÄÁéÃô¶ÈºÍÑ¡ÔñÐÔ¡£

¡¡¡¡2.2.1¡¢µ°°×³Áµí·¨(protein precipitation£¬PPT)

¡¡¡¡½«Ò»¶¨Á¿µ°°×³Áµí¼Á¼ÓÈëÉúÎïÑùÆ·ÖгýÈ¥µ°°×ÖÊ£¬Ê¹Óëµ°°×½áºÏµÄÒ©ÎïÓÎÀëµ½ÓлúÊÔ¼ÁÖУ¬»ìÔÈÀëÐÄ£¬È¡ÉÏÇåÒº½øÐзÖÎö¡£³£Óõĵ°°×³Áµí¼ÁÓÐÒÒëæ¡¢¼×´¼¡¢ÒÒ´¼µÈ£¬¶øpHÖµÊÇÓ°ÏìPPT·¨¶ÔÑùÆ·ÌáÈ¡ÂʺͻØÊÕÂʵÄÖØÒªÒòËØ¡£El-GindyµÈ[18]·Ö±ðÔÚËá¼îÐÔÌõ¼þÏÂÓÃÒÒëæ×÷Ϊµ°°×³Áµí¼Á´¦Àíº¬°¢ÌæÂå¶ûºÍÂÈà­ÍªµÄÈéÖ­ÑùÆ·£¬½á¹û±íÃ÷ÒÒëæºÍÇâÑõ»¯ÄƵÄ×éºÏ²»Äܽ«ÑùÆ·Öеĵ°°×ÖʳÁµíÍêÈ«³Áµí³öÀ´£¬Á½ÖÖÒ©ÎïµÄ»ØÊÕÂʾùµÍÓÚ70%£»¶ø¼ÓÈëÁ×Ëá»òÑÎËáµÄµ°°×³ÁµíЧ¹ûºÃ£¬Á½ÖÖÒ©Îï»ØÊÕÂʾùΪ95%×óÓÒ¡£PPT·¨¿ìËÙ¼ò±ã¡¢³É±¾µÍ£¬µ«²»ÄÜÍêÈ«³ýÈ¥ÈéÖ­ÑùÆ·ÖеĸÉÈÅÎïÖÊ£¬¿ÉÄܵ¼ÖÂÇ¿ÁҵĻùÖÊЧӦ£¬ÇÒ΢Á¿µÄ·ÖÎöÎï¿ÉÄÜËæµ°°×Öʹ²³Áµí¶øËðʧ¡£Í¨³£ÓÃPPT³õ²½³ýÈ¥µ°°×ÖÊ£¬ÔÙÓÃÆäËû·½·¨ÝÍȡŨËõÑùÆ·¡£WolleinµÈ[19]ÓÃÒÒëæ³ýÈ¥º¬Î÷µØÄǷǼ°Æä´úлÎïµÄÈéÖ­ÑùÆ·Öеĵ°°×ÖʺóÀëÐÄ£¬ÉÏÇåÒºÓÃÁ×ËỺ³åÈÜÒºµ÷½ÚpHΪ6ºóתÈëSPEÖù½øÐÐÝÍÈ¡£¬Î÷µØÄǷǺÍN-È¥¼×»ùÎ÷µØÄǷǶ¨Á¿ÏÞ·Ö±ðΪ0.77 ng·mL-1ºÍ0.83 ng·mL-1¡£

¡¡¡¡2.2.2¡¢ÒºÒºÝÍÈ¡·¨£¨liquid-liquid extraction£¬LLE£©

¡¡¡¡LLEÊÇÀûÓ÷ÖÎöÑùÆ·ÔÚË®ºÍÓлúÏàÖзÖÅäϵÊý²»Í¬¶ø±»·ÖÀ룬´ïµ½Ïû³ý¸ÉÈÅÎïÖÊ¡¢´¿»¯±»²âÎïÖʵÄÄ¿µÄ¡£ÔÚÒѱ¨µÀµÄÈéҩŨ¶È²â¶¨µÄÎÄÏ×ÖÐÓõ½µÄÝÍÈ¡ÈܼÁÓÐÒÒÃÑ[20]¡¢¶þÂȼ×Íé[18]¡¢»ìºÏÈܼÁ[21]µÈ¡£Ê¹ÓÃLLE·¨Ê±Ð迼ÂÇÓлúÈܼÁµÄÑ¡Ôñ¡¢Ìå»ý±ÈÒÔ¼°ÌåϵµÄpHµÈ£¬ºÏÊʵÄÓлúÈܼÁºÍpH¿Éʹ»ØÊÕÂÊÔö¼Ó£¬ÖÊÆ×ÏìÓ¦ÔöÇ¿¡£GrimmµÈ[21]±È½ÏÁ˹ÌÏàÝÍÈ¡·¨£¨SPE£©ºÍÌáÈ¡ÈܼÁ·Ö±ðΪÕý¼ºÍé-2-±û´¼£¨99£º1£¬v/v£©£¨A·¨£©¡¢1-Âȶ¡Íé-ÒÒë棨4£º1£¬v/v£©£¨B·¨£©µÄÁ½ÖÖLLE·¨´¦Àíº¬¶¡±ûŵ·È£¨BUP£©ºÍÈ¥¼×»ù¶¡±ûŵ·È£¨norBUP£©µÄÈéÖ­ÑùÆ·µÄ»ØÊÕÂÊ¡£·¢ÏÖB·¨»ØÊÕÂÊ×î¸ß¶øA·¨»ØÊÕÂÊ×îµÍ£¬ÓÃ1-Âȶ¡Íé-ÒÒëæÌáÈ¡Ò©ÎBUPºÍnorBUP±£Áôʱ¼äΪ4.3 minºÍ2.5 min,¶¨Á¿ÏÂÏÞ·Ö±ðΪ0.18 ng·mL-1ºÍ0.20 ng·mL-1¡£ÓÃLLEÌáÈ¡Ò©Îïºó£¬ÌáÈ¡Òº²»ÄÜÖ±½ÓÓÃÓÚ·ÖÎö£¬´ý²â×é·Ö¿ÉÄÜÒò·Ö²¼ÔڽϴóÌå»ýÈܼÁÖжø´ï²»µ½¼ì²âÁéÃô¶ÈÒªÇó£¬Òò´Ë¿ÉÓõªÆø´µ¸ÉÌáÈ¡ÒºÔÙ½«ÑùÆ·ÈܽâÓÚÁ÷¶¯ÏàÖÐÔÙ½øÑù·ÖÎö¡£NakanishiµÈ[20]ÓÃÒÒÃÑÌáÈ¡ÓÒÐýÃÀÍÐßäßòºóÀëÐÄ£¬ÉϲãÓÃÓлúÏà´µ¸Éºó¸´ÈÜ£¬ÎÐÐýÀëÐÄ¡¢¹ýÂ˺ó½øÑù£¬»ØÊÕÂÊΪ82.4%~87.9%¡£

¡¡¡¡LLEÑ¡ÔñÐԸߣ¬¿ÉÒÔÓÐЧ¼õÉÙ»ùÖÊЧӦ£»µ«ÓвÙ×÷·±Ëö¡¢ºÄʱ³¤¡¢ÑùÆ·ÏûºÄÁ¿´ó¡¢²»Ò×ʵÏÖ×Ô¶¯»¯¡¢ÒײúÉúÈ黯ÏÖÏóµÈȱµã£¬ÇÒÝÍÈ¡¹ý³ÌÖÐʹÓõÄһЩ»¯Ñ§ÎïÖÊ¿ÉÄÜ»á¶ÔÒÇÆ÷Ôì³ÉË𻵡£

¡¡¡¡2.2.3¡¢¹ÌÏàÝÍÈ¡·¨£¨solid phase extraction£¬SPE£©

¡¡¡¡SPEÊÇÀûÓò»Í¬ÎïÖÊÔÚ¹ÌÒºÁ½ÏàÖÐÏ໥×÷ÓõIJîÒìʵÏÖ·ÖÀ룬Æä¾ßÌå²Ù×÷ÊÇÏÈʹ±»·ÖÎöÎïÎü¸½µ½¹Ì¶¨ÏàÉÏ,È»ºóʹÓò»Í¬Ï´ÍÑÄÜÁ¦µÄÈÜÒº(Á÷¶¯Ïà)·Ö²½Ï´ÍÑ,ʵÏÖÑùÆ·µÄ·ÖÀë¡¢´¿»¯Ó븻¼¯¡£SPE¿ìËÙ¼ò±ã¡¢ÒýÈëµÄ¸ÉÈÅÎïÖÊÉÙÇÒ¿ÉÒÔ±ÜÃâÈ黯ÏÖÏó£¬ÝÍÈ¡ÖùÓÐC18[22]¡¢C8¡¢Ç¿ÑôÀë×Ó½»»»Öù[23,24]¡¢»ìºÏÐÍÒõÀë×Ó½»»»Öù[25]ºÍHLBÖù[26]¡£ÆäÖУ¬HLBÖùÔØÑùÁ¿½ÏC18´ó£¬»ØÊÕÂʸߣ¬ÇÒÖù¸ÉºÔ²»Ó°Ïì»ØÊÕ£»pHÊÊÓ¦ÐÔ¸ü¹ã£¬ÊʺÏÐÔÖʸ÷ÒìµÄ¶àÖÖÎïÖʵÄÌáÈ¡¡£Martínez-HuelamoµÈ [27]±È½ÏÁËC18¡¢ENV+¡¢HLB¡¢MAX¡¢SDB-RPSÎåÖÖSPEÌåϵ¶Ôβ-ÄÚõ£°·À࿹ÉúËصĻØÊÕÂʺÍÌáȡЧÂÊ£¬·¢ÏÖC18ºÍHLBÖù¶ÔËùÓÐÄ¿±êÇàùËض¼ÓнϸߵĻØÊÕÂʺÍÌáȡЧÂÊ£»µ«HLBÖù±ÈC18Öù»ØÊÕÂʸü¸ß£¬Æä²ÉÓÃ1 mL¼×´¼¡¢1 mLË®ºÍ1 mL 0.1 mmol·L-1Á×ËỺ³åÈÜÒº£¨pH 10£©»î»¯HLBÖù£¬ËæºóÓÃ2 mL¼×´¼Ï´ÍÑÑùÆ·¡£Ö¬ÈÜÐԸߵÄÒ©ÎïÒ×Ðî»ýÔÚÖ¬·¾ÖлòÓëѪ½¬µ°°×½áºÏ£¬Òò´ËÔÚÝÍȡǰʹҩÎïÓÎÀë³öÀ´¿ÉÒÔÌá¸ß»ØÊÕÂÊ¡£ManoharµÈ[24]ÌáÈ¡ÈéÖ­ÖеĴïƥΤÁÖ£¬ÓÃÒÒëæºÍÕý¼ºÍéÆÆ»µÖ¬·¾ÇòºóÀëÐÄ£¬ÉÏÇåҺתÈëMCXÖùÝÍÈ¡£¬´ïƥΤÁÖ¶¨Á¿ÏÂÏÞ´ï10 pg·mL-1£¬Æ½¾ù»ØÊÕÂÊ70.3%¡£ÑùÆ·ÈÜÒºµÄpHÖµÔÚ¹ÌÏàÝÍÈ¡¹ý³ÌÖÐÆð×ÅÖÁ¹ØÖØÒªµÄ×÷Óã¬ÎªÁ˼õÉÙ»ùÖÊЧӦ£¬Ìá¸ßÎü¸½Ð§ÂÊ£¬±ØÐë¿ØÖƺÃÑùÆ·ÈÜÒºµÄpHÖµ¡£¶ÔÓÚһЩÈõËáÐÔºÍÈõ¼îÐÔÒ©Îͨ¹ýµ÷½Ú»º³åÒºpH¸Ä±ä·ÖÎöÎïÀë×Ó»¯³Ì¶È£¬¿ÉÒÔ»ñµÃÀíÏëµÄÝÍȡЧ¹û¡£HouµÈ [26]½«2 gº¬5ÖÖÍ·æß¾úËغÍÈ¥ÒÒõ£Í·æß¾úËصÄÅ£ÈéÑùÆ·Ö±½Ó×¢ÈëHLBÖù£¬½á¹ûÓÐ5ÖÖÍ·æß¾úËØ»ØÊÕÂʵÍÓÚ25%£»¶øÓÃpH 8.5~9.0µÄPBSÏ¡ÊÍÅ£ÄÌÑùÆ·ºó£¬ËùÓдý²âÎïµÄ»ØÊÕÂʾù´ï94%ÒÔÉÏ¡£SPEµÄ¾ÖÏÞÐÔÊǹÌÏàÝÍȡСÖù³É±¾¸ß£¬¶ÔÐí¶àÑùÆ·µÄ¹ÌÏàÝÍÈ¡¿Õ°×Öµ½Ï¸ß£¬ÇÒÁéÃô¶È±ÈLLE²î¡£

¡¡¡¡Ä¿Ç°Ò²ÓÐʵÑéʹÓÃÄÉÃ׿ÅÁ£×÷ΪSPEµÄÎü¸½¼Á£¬Æä¿ÉÒÔÌṩ±È΢Ã×¼¶¿ÅÁ£¸üºÃµÄÝÍÈ¡ÄÜÁ¦ºÍЧÂÊ¡£ShimoyamaµÈ[28]½¨Á¢ÁËÈéÖ­Öп¨ÂíÎ÷ƽŨ¶È²â¶¨µÄHPLC·¨£¬²ÉÓÃC18¹ÌÏàÝÍÈ¡ÖùÝÍÈ¡¿¨ÂíÎ÷ƽ£¬Ï´ÍÑҺΪ5 mL 60%¼×´¼£¬·½·¨¼ì²âÏÞΪ5 ?g·mL-1¡£GhorabaµÈ[29]Ò²²ÉÓÃHPLC·¨²â¶¨¿¨ÂíÎ÷ƽÈéҩŨ¶È£¬Ê¹ÓÃпÐÞÊεÄÄÉÃ×Áò¿ÅÁ£×÷Ϊ¹ÌÏàÝÍÈ¡Îü¸½¼ÁÀ´·ÖÀë¡¢´¿»¯ÈéÖ­ºÍѪ½¬ÑùÆ·ÖеĿ¨ÂíÎ÷ƽ£¬Ï´ÍÑҺΪ250 ?L¼×´¼£¬·½·¨¼ì²âÏÞ½öΪ0.16 ng·mL-1£¬Ó봫ͳSPE·¨Ïà±ÈÓлúÈܼÁʹÓÃÁ¿ÉÙ¡¢ÁéÃô¶È¸ß¡¢ÏßÐԺá£

¡¡¡¡2.2.4¡¢ÆäËû·½·¨

¡¡¡¡Ëæ×ÅÒ©Îï·ÖÎö¼¼ÊõµÄ²»¶ÏÌá¸ß£¬ÉúÎïÑùÆ·Ô¤´¦Àí¼¼ÊõµÃµ½Ñ¸ËÙ·¢Õ¹£¬Ò»Ð©ÐÂÐ˵ÄÉúÎïÑùÆ·Ô¤´¦Àí¼¼Êõ±»Ó¦ÓÃÓÚÈéÖ­ÑùÆ·¡£

¡¡¡¡£¨1£©ÐÂÐÍÒºÒºÝÍÈ¡¼¼Êõ

¡¡¡¡ÒºÒºÝÍȡм¼ÊõÓоùÏàÒºÒºÝÍÈ¡£¨HLLE£©¡¢ÒºÒºÎ¢ÝÍÈ¡£¨LLME£©¡¢Extrelur NTÒºÒºÝÍÈ¡¡£ÆäÖУ¬LLMEÓÉÓÚ±ÈLLE¿ìËÙ¼ò±ã¡¢¸»¼¯±¶Êý´ó¡¢ÝÍȡЧÂʸߡ¢ÓлúÈܼÁÓÃÁ¿ÉÙ£¬ÔÚÉúÎïÑùÆ·Ç°´¦ÀíÖÐÖ𽥵õ½ÔËÓá£LLMEÒÔÂÌÉ«»·±£¡¢Îȶ¨ÐԸߵÄÀë×ÓÒºÌå×÷ΪÝÍÈ¡ÈܼÁ£¬¿ÉÒÔ¿Ë·þ´«Í³ÝÍÈ¡ÈܼÁÒ×»Ó·¢µÄÌص㡣PadróµÈ[30]ÀûÓÃ1-ÐÁ»ù-3-¼×»ùßäßòÁù·úÁ×ËáÑÎ([C8MIM][PF6])Àë×ÓÒºÌåҺҺ΢ÝÍÈ¡£¨IL-DLLME£©HPLC-UV·¨²â¶¨ÈéÖ­ÖÐÜÐÏõßòºÍÏõ߻Ī˾µÄŨ¶È£¬²¢Ê¹ÓÃÖÐÐÄ×éºÏÉè¼Æ·½·¨£¨CCD£©ÕÒµ½ÊµÑé×î¼Ñ¹¤×÷Ìõ¼þ£¬Æ½¾ù»ØÊÕÂÊ·Ö±ðΪ7.5%¡¢89.7%£¬µ±S/N=10.0ʱ£¬ÜÐÏõßòºÍÏõ߻Ī˾¶¨Á¿ÏÂÏÞΪ0.30 ?g·mL-1ºÍ0.20 ?g·mL-1¡£

¡¡¡¡£¨2£©¹ÌÏàÝÍȡм¼Êõ

¡¡¡¡¹ÌÏàÝÍȡм¼Êõ°üÀ¨ÏÞ½øÌîÁϹÌÏàÝÍÈ¡¡¢¹ÌÏà΢ÝÍÈ¡£¨SPME£©ºÍÔÚÏß¹ÌÏàÝÍÈ¡¡£ÏÞ½øÌîÁÏ£¨restricted-access material, RAM£©ÊÇÒ»ÖÖÐÂÐÍÔÚÏßÑùÆ·Ô¤´¦ÀíÌîÁÏ£¬ÆäÔÚÉ«Æ×ÌîÁÏÍâ±íÃæ½øÐÐÇ×Ë®ÐÔÐÞÊδӶø¿ÉÒÔ×èÖ¹ÉúÎïÑùÆ·ÖеĴó·Ö×ÓÎïÖÊÓë¹Ì¶¨Ïà½Ó´¥·¢Éú²»¿ÉÄæµÄ±äÐÔºÍÎü¸½¡£RAM¿É×÷·ÖÎöÖù»òÔ¤´¦ÀíÖùʵÏÖÉúÎïÑùÆ·µÄ×Ô¶¯»¯·ÖÎö£¬µ°°×Öʵȴó·Ö×ÓÔÓÖÊ¿ÉÒÔÖ±½Ó±»Ô¤´¦ÀíÁ÷¶¯ÏàÏ´ÍÑ£¬¶øС·Ö×Ó´ý²â×é·Ö±»¸»¼¯ÔÚÏÞ½øÖùÉÏ¡£RAMÓëÒºÏàÉ«Æ×ÔÚÏßÁªÓÿÉʵÏÖ¸´ÔÓÉúÎïÌåÒºµÄÖ±½Ó½øÑù¶øÎÞÐ踴ÔÓµÄÑùÆ·Ç°´¦Àí²½Öè¡£LopesµÈ[31]½¨Á¢ÁËRAM-BSAÖùͬʱ×÷ΪԤ´¦ÀíÖùºÍ·ÖÎöÖù²â¶¨¿¨ÂíÎ÷ƽ£¨CMZ£©ºÍ»îÐÔ´úл²úÎï10,11-»·Ñõ¿¨ÂíÎ÷ƽ(CMZE)ÈéҩŨ¶ÈµÄLC-IT-MS/MS·¨£¬ÌṩÁËÒ»ÖÖÁéÃô¶È¸ß¡¢ÎÞ»ùÖÊЧӦÇÒ¼¸ºõ²»ÐèÒªÑùÆ·ÖƱ¸µÄ·ÖÎö·½·¨£¬CMZºÍCMZE¼ì²âÏÞ·Ö±ðΪ25 ng·mL-1ºÍ50 ng·mL-1¡£

¡¡¡¡£¨3£©¸ÉÈéµã£¨dried breast-milk spot, DBMS£©²ÉÑù¼¼Êõ

¡¡¡¡¸ÉÈéµã²ÉÑù¼¼ÊõÊǽ«ÈéÖ­ÑùÆ·µÎµ½²ÉÑù¿¨µÄԲȦÄÚºóÊÒÎÂϹýÒ¹ÁÀ¸É£¬½«ÑùÆ·ÊÕ¼¯ÔÚ¿¨Ö½ÉÏ[32]¡£ÓëPPTºÍLLEµÈ´«Í³Ç°´¦Àí·½·¨Ïà±È£¬DBMS·¨ÓÐÑùÆ·ÈÝÁ¿Ð¡¡¢Ò×ÓÚÊÕ¼¯¡¢ÉúÎﰲȫÐԸߡ¢¿É³£Î´¢´æ¡¢ÔËÊä³É±¾µÍ¡¢ÔöǿijЩ·ÖÎöÎïµÄÎȶ¨ÐÔµÈÓŵ㣬µ«²â¶¨½á¹û¿ÉÄÜÊܵãÑùÌõ¼þÓ°ÏìÇÒ²»ÊÊÓÃÓÚ²»Îȶ¨µÄÒ©ÎһЩ¿¹²¡¶¾Ò©µÄÈé֭Ũ¶È²â¶¨²ÉÓô˷¨£¬ÈçÀ­Ã×䶨[33]¡¢ÄÎάÀ­Æ½[34]¡¢ÒÀ·¨Î¤ÂØ[35]µÈ¡£OlagunjuµÈ[35]½«º¬ÒÀ·¨Î¤ÂصÄÈéÖ­ÖƳɸÉÈéµãºóÓôò¿×»úÈ¡Ï·ÅÈëÊÔ¹ÜÖУ¬Óü״¼ÌáÈ¡ºóÉÏÇåÒºÕô¸É£¬¸´ÈÜÓÚÁ÷¶¯ÏàÖнøÑù·ÖÎö£¬·ÖÎöʱ¼äΪ5 min£¬ÒÀ·¨Î¤Âر£Áôʱ¼äΪ2.27 min£¬Æ½¾ù»ØÊÕÂÊ106.4%¡£

¡¡¡¡3¡¢ ÈéÒ©ÎïŨ¶È²â¶¨·½·¨

¡¡¡¡ÌåÄÚÒ©ÎïŨ¶È¼à²â·½·¨Óкܶ࣬ÔÚÒÑ¿ªÕ¹µÄÈéҩŨ¶È¼à²âÖг£Óõķ½·¨ÎªÃâÒß·ÖÎö·¨¼°É«Æ×·¨¡£

¡¡¡¡3.1¡¢ÃâÒß·ÖÎö·¨

¡¡¡¡ÃâÒß·ÖÎö·¨ÊÇ»ùÓÚ¿¹Ô­Ó뿹ÌåÌØÒìÐÔ·´Ó¦½øÐмì²âµÄ·ÖÎöÊֶΣ¬Ö÷ÒªÓÐÓ«¹âÃâÒß·ÖÎö·¨£¨FIA£©¡¢Ã¸ÃâÒß·ÖÎö·¨£¨EIA£©¡¢·ÅÉäÃâÒß·ÖÎö·¨£¨RIA£©µÈ¡£´ËÀà·½·¨¾ßÓÐÌØÒìÐÔÇ¿¡¢³É±¾µÍ¡¢²Ù×÷¼òµ¥¿ìËÙ¡¢ÎÞÐ踴ÔÓµÄÉ豸µÈÌص㣬²»½ö¿ÉÓÃÓڲⶨµ°°×ÖÊ¡¢Ã¸µÈ´ó·Ö×ÓÎïÖÊ£¬¶øÇÒ»¹¹ã·ºÓÃÓڲⶨС·Ö×ÓÒ©ÎÔÚÌåÄÚÒ©Îï·ÖÎöÖÐÒѳÉΪһÖֱز»¿ÉÉٵļà²â¼¼Êõ¡£RaysyanµÈ[36]½¨Á¢ÁË»ùÓÚÈ齺΢Á£µÄ²âÁ÷ÃâÒß·¨À´²â¶¨ÈéÖ­ÖжàÖÖ´ó»·ÄÚõ¥À࿹ÉúËØ£¬·ÖÎöÑùÆ·Óë¹Ì¶¨ÔÚ²âÊÔÏßÉϵIJâÊÔ¿¹Ô­¾ºÕù½áºÏÈ齺¿¹Ìå̽Õ룬¿ÉÓÃÈâÑÛ»òɨÃèÒÇÅжÏÑÕÉ«±ä»¯¡£¸Ã·¨ÄÜÔÚ10 minÄÚÍê³É£¬¶Ô6ÖÖ´ó»·ÄÚõ¥µÄ¼ì²â·¶Î§Îª2.5 ~ 180 ng·mL-1£¬Ã÷ÏÔµÍÓÚ¸øÒ©ºóÈéÖ­ÖÐÕâЩ¿¹ÉúËصÄÔ¤ÆÚŨ¶È£¬Òò´Ë´Ë·¨ÊÊÓÃÓÚ¼à²â¿¹ÉúËØÔÚĸÈéÖеķֲ¼£¬Îª°²È«Ä¸ÈéιÑøÌṩÒÀ¾Ý¡£ZongµÈ[37]½¨Á¢Á˲ⶨÈé·ÛÖÐŵ·úɳÐÇ£¨NOR£©µÄÖ½»ùÓ«¹âÃâÒß·¨£¬ÒÔÁ¿×Óµã±ê¼ÇµÄŵ·úɳÐǵ¥¿Ë¡¿¹Ì壨QDs-Ab£©ÎªÌ½Õëʶ±ðÏàÓ¦µÄNOR£¬Î´Óë´ý²âNOR½áºÏµÄQDs-Ab±»Ö½»ùÉϹ̶¨µÄNOR-BSAżÁªÎﲶ»ñ¶ø²úÉúÓ«¹â£¬¶øÓëNOR½áºÏµÄQDs-AbÔò¿É´ÓÖ½»ùÉÏÏ´È¥£¬·½·¨¼ì²âÏÞΪ10 pg·mL-1¡£´Ë·¨³É±¾µÍ¡¢Ñ¡ÔñÐԸߡ¢ÁéÃô¶È¸ß£¬ÇÒÖ½ÖÊ·ÖÎö×°ÖþßÓÐÂÌÉ«»·±£¡¢·ÖÎöËٶȿ졢Ñù±¾Á¿Ð¡¡¢Ð¯´ø·½±ãµÈÓŵ㡣ÃâÒß·ÖÎö·¨ËäÈ»¾ßÓнϸߵÄÁéÃô¶ÈºÍÑ¡ÔñÐÔÇÒÎÞÐè¶ÔÑùÆ·½øÐи´ÔÓµÄÇ°´¦Àí£¬µ«²â¶¨²½Öè¶àÇÒ²»ÄܶԶàÖÖÒ©Îïͬʱ¼ì²â¡£Ò©ÎÌ廹¿ÉÄÜÓë½á¹¹Ïà½üµÄ´úл²úÎï¡¢ÄÚÔ´ÐÔÎïÖÊ·¢Éú½»²æ·´Ó¦¶øÒýÆðÎó²î£¬Òò´ËÃâÒß·ÖÎö·¨Ó¦¾¡Á¿Ìá¸ß·´Ó¦×¨ÊôÐÔ£¬¾¡¿ÉÄܱÜÃâ»ò¼õÉÙÎó²î¡£

¡¡¡¡3.2 ¡¢É«Æ×·¨

¡¡¡¡É«Æ×·¨°üÀ¨±¡²ãÉ«Æס¢ÆøÏàÉ«Æ×£¨GC£©¡¢¸ßЧҺÏàÉ«Æ×£¨HPLC£©µÈ¡£GCÊܽøÑùÌõ¼þÏÞÖÆ£¬ÔÚÈéҩŨ¶È²â¶¨ÖÐÓ¦ÓýÏÉÙ£»¶øHPLCºÍGCÏà±È£¬¹Ì¶¨ÏàÖÖÀà¸ü¶à¡¢Á÷¶¯ÏàÑ¡Ôñ·¶Î§¸ü¹ãÇÒ²»ÊÜÑùÆ·»Ó·¢ÐÔºÍÎȶ¨ÐÔµÄÏÞÖÆ£¬ÔÚÌåÄÚÒ©Îï·ÖÎöÖÐÓ¦Óøü¹ã·º¡£ÒºÏàÉ«Æ×·¨·ÖΪҺÏàÉ«Æ×·ÖÀëºÍÖÊÆ×¼ì²âÁ½²¿·Ö£¬»¯ºÏÎï¾­É«Æ×Öù·ÖÀëºó£¬ÔÙ½øÈë¼ì²âÆ÷½øÐмø¶¨¡£HPLC·ÖÀëЧÂʸߣ¬µ«ÁéÃô¶È½ÏµÍ£¬¼ø¶¨ÄÜÁ¦²»×㣬¶¨Á¿ÏÂÏÞ¶àΪ΢¿Ë¼¶£»ÇÒHPLC·¨Ñ¡ÔñÐԲ¶ÔÓÚδ֪³É·ÖµÄÑùÆ·ÄÑÒÔ¶¨ÐÔ¡£ÔÚÌåÄÚÒ©Îï·ÖÎöÖУ¬Ñª½¬¡¢ÄòÒº¡¢ÈéÖ­µÈÉúÎïÑùÆ·Öб»²âÒ©ÎïÍùÍùŨ¶È½ÏµÍ£¬¸ÉÈÅÔÓÖʽ϶࣬ÀûÓÃHPLC·ÖÎöÍùÍù¼ì²âÁéÃô¶ÈºÍרÊôÐÔ´ï²»µ½ÒªÇó¡£ÖÊÆ×ÒǾßÓкܺõĶ¨ÐÔÄÜÁ¦¼°¸ßÑ¡ÔñÐÔ¡¢¸ßÁéÃô¶È£¬ÇÒ¿ÉÒÔ»ñµÃ·á¸»µÄ»¯ºÏÎï½á¹¹ÐÅÏ¢¡£ÒºÖÊÁªÓ÷¨½«ÖÊÆ×ÒÇ£¨MS£©×÷ΪHPLCµÄ¼ì²âÆ÷£¬¿ÉÒÔ½«É«Æ׵ĸ߷ÖÀëÄÜÁ¦ºÍMSµÄÇ¿¶¨ÐÔ¹¦ÄܽáºÏÆðÀ´£¬Ôںܴó³Ì¶ÈÉÏÀ©Õ¹ÁËHPLCµÄÓ¦Ó÷¶Î§£¬Òò´Ë±»¹ã·ºÓ¦ÓÃÓÚÌåÄÚÒ©Îï·ÖÎö£¬ÔÚÒÑÓеÄÈéҩŨ¶ÈÑо¿Öдó¶à²ÉÓÃÒºÖÊÁªÓ÷¨¡£

¡¡¡¡3.2.1¡¢ ·ÖÀëϵͳ

¡¡¡¡£¨1£©·´ÏàÉ«Æ×·¨

¡¡¡¡·´ÏàÉ«Æ×·¨ÖвÉÓõÄÉ«Æ×ÖùÓÐC18[38]¡¢C8¡¢Çè»ùÖù[18]µÈ£¬ÆäÖУ¬C18ÖùÊÇÈéҩŨ¶È²â¶¨×î³£ÓõÄÉ«Æ×Öù£¬Á÷¶¯ÏೣѡÔñÒÒëæ-Ë®¡¢¼×´¼-Ë® µÈ¡£Èô´ý²âÎï±¾Éí¾ßÓÐËá¼îÐÔ£¬ÏòÁ÷¶¯ÏàÖмÓÈëËá¼îµ÷½Ú¼Á¿ÉÒÔµ÷½Ú·ÖÎöÎï±£Áôʱ¼ä£¬ÓÅ»¯É«Æ×·åÐΡ£ÆäÖУ¬¼×Ëá¡¢ÒÒËá¡¢´×Ëáï§ÊÇʹÓÃ×î¶àµÄËá¼îµ÷½Ú¼Á¡£É«Æ×Ï´ÍÑ·½Ê½·ÖΪÌݶÈÏ´ÍѺ͵ȶÈÏ´ÍÑ¡£ÌݶÈÏ´ÍÑÌõ¼þ¼òµ¥¡¢¶ÔÒÇÆ÷ÒªÇ󲻸ߣ¬µ«·ÖÎöʱ¼ä½Ï³¤£»µ±Ò©ÎïÓë¸ÉÈÅÎïÖʼ«ÐÔÏà²î´óʱ£¬²ÉÓÃÌݶÈÏ´ÍÑ¿ÉÒÔÔڽ϶Ìʱ¼äÄÚ½«·ÖÎöÎï·ÖÀ룬µ«ÌݶÈÏ´ÍѱȵȶÈÏ´ÍѸüΪ¸´ÔÓ¡¢À§ÄÑ¡£Òò´Ë£¬ÔÚÄÜ´ïµ½½ÏºÃ·ÖÀë¶ÈµÄÇé¿öÏÂÓÅÏÈʹÓõȶÈÏ´ÍÑ¡£SalazarµÈ[39]ÀûÓÃLC-MS·¨²â¶¨ÈéÖ­ÖÐÎåÖÖ¿¹ÒÖÓôҩʱ£¬ÎªÑ¡Ôñ×î¼ÑʵÑéÌõ¼þ¶Ô²»Í¬µÄpHÖµ¡¢Á÷ËÙ¡¢ºæÏäζȡ¢»º³åÒºµÄÁ¿Å¨¶ÈºÍÁ÷¶¯Ïà×é³É½øÐÐÁ˲ⶨ£¬ÔÚ×îÓÅÌõ¼þÏ·ÖÎöÎï¿ÉÒÔÔڵȶÈÏ´ÍÑÖб»·ÖÀë²â¶¨¡£ÊµÑé½á¹û±íÃ÷×î¼ÑÁ÷¶¯ÏàΪÒÒëæ-ÒÒËá炙º³åÒº(pH 6.0; 20 mmol/L) (75:25, v/v)£¬´ËʱɫÆ×¾ßÓнϺõķåÐΡ¢¹âÆ×ÏìÓ¦ºÍÁéÃô¶È£»²ÉÓÃC8ÖùʱµÄ×î¼ÑÁ÷ËÙΪ0.7 mL·min-1£¬¸ÃÁ÷ËÙÏÂËùÓл¯ºÏÎïµÄÉ«Æ×·ÖÀëЧ¹û¸üºÃ¡£

¡¡¡¡·´ÏàÉ«Æ×·¨ÓëÖÊÆ×ÁªÓúó£¬ËùÐèÑù±¾Á¿Ð¡¡¢Ñ¡ÔñÐÔºÍÁéÃô¶È¸ü¸ß¡¢ÌØÒìÐÔ¸üÇ¿£¬¶¨Á¿ÏÂÏÞ¿É´ïng·mL-1ÉõÖÁpg·mL-1¡£Phyo Lwin[40]µÈ½¨Á¢Á˲ⶨÈéÖ­ºÍѪ½¬Öа¢ÌæÂå¶ûŨ¶ÈµÄLC-MS/MS·¨£¬²ÉÓÃC18Öù£¬ÌݶÈÏ´ÍÑ£¬±£Áôʱ¼äΪ2 min£¬Ã»ÓлùÖÊЧӦµÄ¸ÉÈÅ£¬Ñª½¬ºÍÈéÖ­ÖеĶ¨Á¿ÏÞ¾ùΪ0.5 ng·mL-1£»¶øEl-Gindy[18]µÈ²ÉÓÃÇè»ùÖù£¬ÒÒëæ-Ë®£¨35:65£¬v/v£¬pH 4.0£©Á÷¶¯ÏàÌåϵ£¬ÌݶÈÏ´ÍÑ£¬½¨Á¢Á˲ⶨÈéÖ­Öа¢ÌæÂå¶ûºÍÂÈàçͪµÄHPLC-UV·¨£¬°¢ÌæÂå¶ûºÍÂÈàçͪ¶¨Á¿ÏÂÏÞΪ0.3 ?g·mL-1ºÍ0.25 ?g·mL-1¡£

¡¡¡¡£¨2£©¶þάɫÆ×·¨

¡¡¡¡·ÖÀë³É·Ö¸´ÔÓµÄÈéÖ­ÖеÄÑùÆ·ÐèÒª·ÖÀëÄÜÁ¦¸üÇ¿µÄ·½·¨£¬¶ø¶þάɫÆ×ÄÜʹÑùÆ·×é·ÖÔÚÁ½¸ö²»Í¬µÄ·ÖÀëÌõ¼þϽøÐзÖÀ룬ÏÔ×ÅÌá¸ßÁË·ÖÀëÄÜÁ¦£¬ÔÚÉúÎïÑùÆ··ÖÀëÖÐÏÔʾ³öÁ˼«´óµÄÓÅÊÆ¡£LopesµÈ[41]ÒÔRAM-BSA C8ΪԤ´¦ÀíÖù£¬C18ÖùΪ·ÖÎöÖù£¬²â¶¨³õÈéºÍ³ÉÊìÈéÖзúÎ÷Í¡ºÍÈ¥·úÎ÷Í¡µÄŨ¶È¡£´Ë·¨´ó·ù¶È¼õÉÙ»ùÖÊЧӦ¡¢ÁéÃô¶È¸ß¡¢ÑùÆ·Ç°´¦Àí¼òµ¥£¬·ÖÎöʱ¼ä½öÐè12 min£¬ÈܼÁÓÃÁ¿ÉÙ£¬·úÎ÷Í¡ºÍÈ¥·úÎ÷Í¡µÄ¶¨Á¿ÏÂÏÞ·Ö±ðΪ3 ng·mL-1¡¢4 ng·mL-1¡£

¡¡¡¡£¨3£©³¬¸ßЧҺÏàÉ«Æ×

¡¡¡¡UHPLCÓ봫ͳµÄHPLCÏà±ÈµÄ·ÖÎöËٶȡ¢ÁéÃô¶È¼°·ÖÀë¶È¸ü¸ß£¬·ÖÎöʱ¼äËõ¶Ì£¬ÈܼÁÓÃÁ¿¼õÉÙ¡£ÀûÓÃUPLC¿ÉÒԺܺýâ¾ö³É·Ö¸´ÔÓ¡¢·ÖÀëÀ§ÄѵÈÎÊÌ⣬Òò´Ë¿ÉÒÔÓÃÓÚ·ÖÎö³É·Ö¸´ÔÓµÄÈéÖ­¡£Ä¿Ç°£¬ÀûÓÃUPLC-MS/MS·¨²â¶¨ÈéҩŨ¶ÈµÄÒ©ÎïÓп¹ÉúËØÀà[26,42]¡¢¿¹²¡¶¾Ò©[43,44]¡¢¿¹ÄýÒ©[51]µÈ¡£ManoharµÈ[24]½¨Á¢ÁËUPLC-MS/MS·¨¶¨Á¿²â¶¨ÈËÈéÖдïƥΤÁÖ£¬Á÷¶¯ÏàΪº¬1%¼×ËáµÄË®£¨A£©ºÍº¬1%¼×ËáµÄÒÒë棨B£©£¬ÌݶÈÏ´ÍÑ£¬·ÖÎöʱ¼ä½ö3 min£¬¶¨Á¿ÏÂÏÞ´ï10 pg·mL-1¡£

¡¡¡¡£¨4£©ÊÖÐÔÉ«Æ×·¨

¡¡¡¡Ò»Ð©Ò©Îï¼°Æä´úл²úÎïΪÊÖÐÔ»¯ºÏÎµ«×óÐýÌåºÍÓÒÐýÌå·Ö×ÓÁ¿ÏàµÈµ«Ò©Àí»îÐÔ²»Í¬£¬ÀûÓ÷´ÏàÉ«Æ×ÖùÎÞ·¨½«Æä·ÖÀë¡£ÔÚÊÖÐÔÉ«Æ×ÖУ¬ÊÖÐÔÒì¹¹·Ö×ÓÓë¹Ì¶¨Ïà»òÁ÷¶¯Ïà×÷ÓÃת»¯Îª·Ç¶ÔÓ³Ìå¶ø±»·Ö¿ª¡£Î÷̪ÆÕÀ¼£¨CIT£©¼°Æä´úл²úÎïDCITºÍDDCIT¶¼ÊÇÊÖÐÔ»¯ºÏÎÓÒÐýÎ÷̪ÆÕÀ¼ºÍÉÙÁ¿µÄDCITÆðÖ÷ÒªÒ©Àí×÷Óá£WeisskopfµÈ [23]½¨Á¢Á˲ⶨCITºÍDCIT¶ÔÓ³ÌåµÄÊÖÐÔÉ«Æ×-ÖÊÆ×ÁªÓ÷¨£¬³É¹¦·ÖÀëCITºÍDCIT¶ÔÓ³Ìå²¢¶¨Á¿¡£´Ë·¨Ñ¡ÔñµçÅçÎíµçÀëÔ´ºÍMRMģʽ£¬Á÷¶¯ÏàΪ´×Ëá泥¨20 mmol·L-1, pH 9.0£©-ÒÒëæΪÁ÷¶¯Ï࣬ÌݶÈÏ´ÍÑ£¬CIT¶ÔÓ³Ì嶨Á¿ÏÂÏÞΪ0.1 ng·mL-1£¬DCIT¶ÔÓ³Ì嶨Á¿ÏÂÏÞΪ0.3 ng·mL-1¡£

¡¡¡¡3.2.2 ¡¢¼ì²âϵͳ

¡¡¡¡HPLC³£Óõļì²âÆ÷ÓÐ×ÏÍâ¡¢Ó«¹â¡¢µç»¯Ñ§¡¢Õô·¢¹âÉ¢Éä¼ì²âÆ÷µÈ¡£ÔÚÒѱ¨µÀµÄHPLC·¨²â¶¨ÈéÖ­ÖÐÒ©ÎïŨ¶ÈµÄÎÄÏ×ÖУ¬²ÉÓõļì²âÆ÷Ò»°ãΪ×ÏÍâ¼ì²âÆ÷[28]ºÍÓ«¹â¼ì²âÆ÷[45,46]¡£ÔÚÒÔMS¼°´®ÁªÖÊÆ×£¨MS/MS£©×÷Ϊ¼ì²âÆ÷µÄÒºÖÊÁªÓ÷¨£¨LC-MS/MS£©ÖУ¬MS /MS·ÖÎöµÄÓÐ×ÓÀë×ÓɨÃ衢ĸÀë×ÓɨÃè¡¢ÖÐÐÔ¶ªÊ§¡¢Óе¥Àë×Ó¼à²â£¨SIM£©¡¢Ñ¡Ôñ·´Ó¦¼à²â(SRM)¡¢¶à·´Ó¦¼à²â(MRM)µÈɨÃèģʽ¡£ÆäÖУ¬SIMÊÇÕë¶ÔÒ»¼¶ÖÊÆ׶øÑԵģ¬¼´Ö»É¨Ò»¸öÀë×Ó£»¶øSRMÊÇÕë¶Ô¶þ¼¶»ò¶à¼¶ÖÊÆ×µÄijÁ½¼¶Ö®¼äµÄɨÃèģʽ£¬¼´Ñ¡ÔñÒ»¸öÌØÕ÷ĸÀë×Ó×öMS/MS£¬ÔÚÆäËéƬÖÐÑ¡ÔñÒ»¸öÌØÕ÷×ÓÀë×Ó×÷Ϊ¼à²âÀë×Ó¡£MRMÊÇָͬʱ²â¶¨¶àÖÖ»¯ºÏÎïʱ£¬¶à¸öSRMͬʱ½øÐУ¬Òò´ËÌصãÓëSRMÏàËÆ¡£Ïà½ÏÓÚSIM£¬SRMºÍMRMÁéÃô¶ÈºÍÐÅÔë±È¸ü¸ß£¬ÅÅ»ùÖʸÉÈÅÄÜÁ¦¸üÇ¿£¬·ÖÎö»ùÖʸ´ÔÓµÄÑùƷʱ¾ßÓиü¸ßµÄ·Ö±æÂÊ¡£ÔÚÀûÓÃÒºÖÊÁªÓ÷¨¼à²âÈéҩŨ¶ÈµÄÎÄÏ×ÖУ¬Ëù²ÉÓõÄÖÊÆ×ÒÇÓе¥ÖØËļ«¸ËÖÊÆ×ÒÇ£¨QMS£©¼°´®ÁªÖÊÆ×£¨MS/MS£©£¬MS/MSÓÖ°üÀ¨ÈýÖØËļ«¸ËÖÊÆ×ÒÇ£¨QQQ£©¡¢ÈýÖØËļ«¸Ë-ÏßÐÔÀë×ÓÚåÖÊÆ×ÒÇ£¨QTRAP£©¡¢Ëļ«¸Ë·ÉÐÐʱ¼ä´®ÁªÖÊÆ×£¨QTOF£©µÈ¡£

¡¡¡¡1.QMS

¡¡¡¡QMS½á¹¹¼òµ¥£¬·Ö±æÂʵͣ¬É¨Ãèģʽ¿ÉÑ¡ÔñȫɨÃè»òSIM¡£QMSµÄȫɨÃèģʽֻÄÜ»ñµÃ»¯ºÏÎïµÄ·Ö×ÓÁ¿£»Ïà¶ÔÓÚȫɨÃ裬SIMģʽÁéÃô¶È½Ï¸ß¡¢¶¨Á¿ÄÜÁ¦½ÏÇ¿£¬ÔÚÑùÆ·»ùÖʲ»Ì«¸´ÔÓʱɨÃèЧ¹û½ÏºÃ¡£µ«QMSÓÉÓÚÎÞ´®ÁªÄÜÁ¦¡¢ÌØÒìÐԽϲ¶¨ÐÔÄÜÁ¦²»×㣬ÒÑÖð½¥±»¸ü¸ß·Ö±æÂʵÄÖÊÆ×»òÕß´®ÁªÖÊÆ×È¡´ú¡£

¡¡¡¡2.MS/MS

¡¡¡¡MS/MSÊǽ«Á½¼¶»òÁ½¼¶ÒÔÉϵÄÖÊÁ¿·ÖÎöÆ÷´®ÁªÆðÀ´Ê¹Ó㬱»²âÎïÔÚÀë×ÓÔ´±»Àë×Ó»¯ºó£¬¾­µÚÒ»¼¶ÖÊÆ×Ñ¡Ôñ¸ÐÐËȤµÄÀë×Ó´«ËÍÖÁÅöײÊÒ£¬²úÉúµÄһϵÁÐËéƬÀë×ÓÓɵڶþ¼¶ÖÊÆ×½øÒ»²½·ÖÀë·ÖÎö£¬×îºóµ½´ï¼ì²âÆ÷¼ì²â£¬²úÉúÏàÓ¦µÄÖÊÆ×ͼ¡£MS/MS¿ÉÒÔÌṩ¸ü·á¸»µÄ½á¹¹ÐÅÏ¢£¬ÌرðÊʺÏÓÃÓÚ×é³É³É·Ö¸´ÔÓÇÒ¸ÉÈÅÎïÖʶàµÄÑùÆ·Öеͺ¬Á¿×é·ÖµÄ·ÖÎö²â¶¨¡£ÔÚÈéÖ­Ò©ÎïŨ¶È²â¶¨Öжཫ´®ÁªÖÊÆ×·¨ÓëÉ«Æ×·¨ÁªÓÃÒԴӳɷָ´ÔÓµÄÈéÖ­»ùÖÊÖо¡¿ÉÄÜ»ñµÃ¸ü¶àµÄ·Ö×ÓÀë×ÓºÍËéƬÀë×ÓµÄÐÅÏ¢¡£

¡¡¡¡£¨1£©QQQ

¡¡¡¡QQQÊÇÓÉÁ½¸öµ¥ÖØËļ«¸Ëͨ¹ýÖмäµÄÅöײÊÒ´®ÁªÆðÀ´£¬¾ßÓÐSRM¡¢MRM¡¢Ä¸Àë×ÓɨÃè¡¢ÖÐÐÔ¶ªÊ§¡¢×ÓÀë×ÓɨÃèµÈ¹¦ÄÜ¡£Óëµ¥ÖØËļ«¸ËÏà±È£¬QQQÑ¡ÔñÐÔºÍÁéÃô¶È¸ü¸ß£¬ÔÚÖ´ÐÐÖÐÐÔ¶ªÊ§É¨ÃèºÍĸÀë×ÓɨÃèģʽʱ¾ßÓÐ×îºÃµÄÁéÃôÐÔºÍ׼ȷÐÔ£¬ÊÇÈéҩŨ¶È²â¶¨ÖÐ×ʹÓõÄÖÊÆ×ÒÇ[47,48,49,50,51,52]¡£ÔÚÒÑ¿ªÕ¹µÄÈéҩŨ¶È²â¶¨ÖУ¬QQQ¶à²ÉÓÃSRM»òMRMģʽ[26,53,54]¡£Ma[55]µÈ²ÉÓÃÒºÏà-´®ÁªÈýÖØËļ«¸ËÖÊÆ×ÒÇ·ÖÎöÅ£ÈéÖÐ12ÖÖÌÇƤÖʼ¤ËزÐÁô£¬ÔÚMRMÕýÀë×ÓģʽÏ£¬Ñ¡Ôñ[M+H]+×÷ΪËùÓÐÌÇƤÖʼ¤ËصÄĸÀë×Ó£¬¼à²âʧȥH2OºÍHFµÄËéƬÀë×Ó£¬ÌÇƤÖʼ¤Ëض¨Á¿ÏÞÔÚ0.01¡«0.5 ?g·kg-1·¶Î§ÄÚ¡£QQQÔÚ¶¨Á¿·ÖÎö·½Ãæ¾ßÓкܺõÄÁéÃô¶ÈºÍÖØÏÖÐÔ£¬µ«Æ䶨ÐÔÄÜÁ¦ÈÔ²»¹»ºÃ£¬²»ÊÇ»ñÈ¡ÖÊÆ×ͼ»ò¾«È·ÖÊÁ¿Êý×îºÃµÄÒÇÆ÷¡£Ëæ×Å¿Æѧ¼¼ÊõµÄ·¢Õ¹£¬ÔÚQQQµÄ»ù´¡ÉÏÓÖÖÆÔì³öÁËÁéÃô¶È¸ü¸ß¡¢¶¨ÐÔ·ÖÎöÄÜÁ¦¸üºÃµÄQTRAPºÍQTOFÖÊÆ×ÒÇ¡£

¡¡¡¡£¨2£©QTRAP

¡¡¡¡QTRAP½«ÈýÖØËļ«¸ËÖÐ×îºóÒ»¼¶Ëļ«¸Ë£¨Q3£©¸ÄΪÏßÐÔÀë×ÓÚ壬ʹµÃQ3ͬʱ¾ßÓÐÏßÐÔÀë×ÓÚ嶨ÐÔ¹¦Äܺʹ«Í³Ëļ«¸Ë¶¨Á¿¹¦ÄÜ¡£Ó봫ͳÈýÖØËļ«¸ËÏà±È£¬QTRAPÁéÃô¶È¸ü¸ßÇҿɵõ½¸ü·á¸»µÄÐÅÏ¢Á¿£¬Òò´ËÔÚÈéÖ­Ò©ÎïŨ¶È²â¶¨ÖÐÒ²µÃµ½ÁËÓ¦ÓÃ[56,57,58,59]¡£QTRAPËù¾ßÓеÄIDA¼¼Êõ»¹¿ÉÒÔ½øÐдúлÎï¼ø¶¨£¬Ô¤¹À´úл;¾¶¡£WolleinµÈ[19]²ÉÓÃLC-MS/MS·¨¼ì²âĸÈéÖÐÎ÷µØÄǷǼ°Æä´úл²úÎÔÚMRMģʽÏ£¬ÀûÓÃQTRAPÀë×ÓÚåɨÃèģʽʶ±ðµ½N-È¥¼×»ùÎ÷µØÄÇ·ÇÅԱ߻¹ÓÐÁ½¸ö´úл²úÎï²¢¾Ý´Ë·ÖÎöÁËÎ÷µØÄÇ·Ç´úл;¾¶¡£

¡¡¡¡£¨3£©QTOF

¡¡¡¡QTOFÊÇËļ«¸ËÓë·ÉÐÐʱ¼äÖÊÁ¿·ÖÎöÆ÷µÄ´®Áª£¬ÒÔQMSΪÖÊÁ¿¹ýÂËÆ÷£¬·ÉÐÐʱ¼äÖÊÆ×ÒÇΪÖÊÁ¿·ÖÎöÆ÷¡£LwinµÈ [60]ÀûÓÃLC-MS/MS·¨·ÖÎöÈéÖ­ÖÐÅàßáÆÕÀû¼°Æä´úл²úÎïÅàßáÆÕÀûÀ­Å¨¶Èʱ£¬ÓÃQQQ¼ì²âÅàßáÆÕÀû£¬QTOF¼ì²âÅàßáÆÕÀûÀ­£¬¶¨Á¿ÏÂÏÞ¾ùΪ0.5 ng/mL¡£QTOFÁéÃô¶È¸ß¡¢·ÖÎöËٶȿ졢¿ÉÒÔÌṩ¸ß·Ö±æÂʶþ¼¶Í¼Æ×£¬¶¨ÐÔÄÜÁ¦ÓÅÓÚQQQ£¬µ«ÔÚ¶¨Á¿·ÖÎö·½ÃæµÄÁéÃô¶È²»ÈçQQQ¡£Òò´Ë£¬ÒºÖÊÁªÓ÷¨²â¶¨ÈéҩŨ¶ÈÖÐʹÓÃ×î¶àµÄÖÊÆ×ÒÇ»¹ÊÇQQQ¡£

¡¡¡¡4 ¡¢×ܽáÓëÕ¹Íû

¡¡¡¡²â¶¨ÈéÖ­ÖеÄÒ©ÎïŨ¶È¶ÔÆÀ¹ÀÒ©ÎïÔÚ²¸ÈéÆÚʹÓõݲȫÐÔÊ®·ÖÖØÒª¡£Ä¿Ç°ÒѽøÐÐÈéҩŨ¶È¼à²âµÄÒ©Îﻹ²»¶à£¬ÈéÖ­Öеĸ´ÔӳɷֶÔÒ©ÎïŨ¶ÈµÄ²â¶¨´øÀ´ÁËÒ»¶¨µÄÀ§ÄÑ£¬ÑùÆ·Ç°´¦ÀíÈÔÊÇÈéҩŨ¶È²â¶¨µÄÆ¿¾±¡£ÓÐЧµÄÑùÆ·Ô¤´¦Àí·½·¨ÄܼõÉÙ»ùÖÊЧӦ¡¢Ìá¸ß¼ì²âµÄÁéÃô¶ÈºÍ׼ȷÐÔ£¬Òò´Ë¿ª·¢ºÍÍêÉÆÇ°´¦Àí·½·¨¶ÔÈéҩŨ¶È²â¶¨Ê®·ÖÖØÒª¡£½¨Á¢×¼È·¡¢¿ìËÙ¡¢Îȶ¨µÄÁÙ´²Ñù±¾¼à²â·½·¨ÊÇÁÙ´²³£¹æ¿ªÕ¹ÈéҩŨ¶È¼à²â¡¢±£Õϲ¸ÈéÆÚ¸¾Å®ºÏÀí°²È«ÓÃÒ©µÄ¹Ø¼ü¡£µ«ÏÖÓеÄÈéҩŨ¶È²â¶¨¼ì²â·½·¨¸÷ÓÐÆäÓÅÊÆ£¬Òò´ËÐèÒª½áºÏÒ©ÎïÀí»¯ÐÔÖÊÒÔ¼°ÔÚÈéÖ­ÖеĴæÔÚÐÎʽÁé»îÑ¡ÓÃÈéҩŨ¶È¼à²â·½·¨¡£×ÜÖ®£¬ÈéҩŨ¶È¼à²âÔÚ¿ª·¢¸üиüÀíÏëµÄÒ©ÎïÈé֭Ũ¶È²â¶¨¼¼Êõ¡¢½¨Á¢¸ü¿ÆѧºÏÀíÈéҩŨ¶È¼ì²â·½·¨µÈ·½ÃæÈÔÓкܶ๤×÷Òª×ö¡£

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡[1] Ademollo N, Ferrara F, Delise M, et al. Nonylphenol and octylphenol in human breast milk[J]. Environ Int, 2008, 34(7): 984-987.
¡¡¡¡[2] Verstegen RHJ, Ito S. Drugs in lactation[J]. J Obstet Gynaecol Res, 2019, 45(3): 522-531.
¡¡¡¡[3] Spencer B. Medications and Breastfeeding for Mothers With Chronic Illness[J]. J Obstet Gynecol Neonatal Nurs, 2015, 44(4),543-552.
¡¡¡¡[4] Ito S, Lee A. Drug excretion into breast milk--overview[J]. Adv Drug Deliv Rev, 2003, 55(5): 617-627.
¡¡¡¡[5] Anderson PO. Drugs in Lactation[J]. Pharm Res, 2018, 35(3): 45.
¡¡¡¡[6] Newton ER, Hale TW. Drugs in Breast Milk[J]. Clin Obstet Gynecol, 2015, 58(4): 868-884.
¡¡¡¡[7] Anderson PO, Sauberan JB. Modeling drug passage into human milk[J]. Clin Pharmacol Ther, 2016, 100(1): 42-52.
¡¡¡¡[8] Bailey B, Ito S. Breast-feeding and maternal drug use[J]. Pediatr Clin North Am, 1997, 44(1): 41-54.
¡¡¡¡[9] Breitzka RL, Sandritter TL, Hatzopoulos FK. Principles of drug transfer into breast milk and drug disposition in the nursing infant[J]. J Hum Lact, 1997, 13: 155-158.
¡¡¡¡[10] Bzikowska-Jura A, Sobieraj P, Szostak-W?gierek D, et al. Impact of Infant and Maternal Factors on Energy and Macronutrient Composition of Human Milk[J]. Nutrients, 2020, 12(9): 2591.
¡¡¡¡[11] Welch RM, Findlay JW. Excretion of drugs in human breast milk[J]. Drug Metab Rev, 1981, 12(2): 261-277.
¡¡¡¡[12] Becker GE, Smith HA, Cooney F. Methods of milk expression for lactating women[J]. Cochrane Database Syst Rev, 2016, 9(9): CD006170.
¡¡¡¡[13] Begg EJ, Duffull SB, Hackett LP, et al. Studying drugs in human milk: time to unify the approach[J]. J Hum Lact, 2002, 18(4): 323-332.
¡¡¡¡[14] Anderson PO, Momper JD. Clinical lactation studies and the role of pharmacokinetic modeling and simulation in predicting drug exposures in breastfed infants[J]. J Pharmacokinet Phar, 2020, 47(4): 295-304.
¡¡¡¡[15] Qin Y, Shi W, Zhuang J, et al. Variations in melatonin levels in preterm and term human breast milk during the first month after delivery[J]. Sci Rep, 2019, 9(1): 17984.
¡¡¡¡[16] Plaza-Zamora J, Sabater-Molina M, Rodríguez-Palmero M, et al. Polyamines in human breast milk for preterm and term infants[J]. J Hum Nutr Diet, 2013, 110(3): 524-528.
¡¡¡¡[17] Lopes BR, Barreiro JC, Cass QB. Bioanalytical challenge: A review of environmental and pharmaceuticals contaminants in human milk[J]. J Pharm Biomed Anal, 2016, 130: 318-325.
¡¡¡¡[18] El-Gindy A, Sallam S, Abdel-Salam RA. HPLC method for the simultaneous determination of atenolol and chlorthalidone in human breast milk[J]. J Sep Sci, 2008, 31(4): 677-682.
¡¡¡¡[19] Wollein U, Schech B, Hardt J, et al. Determination and quantitation of sildenafil and its major metabolite in the breast milk of a lactating woman[J]. J Pharm Biomed Anal, 2016, 120: 100-105
¡¡¡¡[20] Nakanishi R, Yoshimura M, Suno M, et al. Detection of dexmedetomidine in human breast milk using liquid chromatography-tandem mass spectrometry: Application to a study of drug safety in breastfeeding after Cesarean section[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2017, 1040: 208-213.
¡¡¡¡[21] Grimm D, Pauly E, P?schl J,et al. Buprenorphine and norbuprenorphine concentrations in human breast milk samples determined by liquid chromatography-tandem mass spectrometry[J]. Ther Drug Monit, 2005, 27(4): 526-530.
¡¡¡¡[22] Rezk NL, White N, Bridges AS, et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications[J]. Ther Drug Monit, 2008, 30(5): 611-619.
¡¡¡¡[23] Weisskopf EP, Aud A, Nguyen KA, et al. Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry[J]. J Pharm Biomed Anal, 2016, 131: 233-245.
¡¡¡¡[24] Manohar M, Marzinke MA. Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk[J]. Clin Biochem, 2020, 82: 66-72.
¡¡¡¡[25] Devreese M, Maes A, De Baere S, et al. Comparative method validation for closantel determination in cattle and sheep milk according to European Union Volume 8 and Veterinary International Conference on Harmonization guidelines[J]. J Chromatogr A, 2014, 1353: 106-113.
¡¡¡¡[26] Hou XL, Wu YL, Lv Y, et al. Development and validation of an ultra high performance liquid chromatography tandem mass spectrometry method for determination of 10 cephalosporins and desacetylcefapirin in milk[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2013, 931: 6-11.
¡¡¡¡[27] Martínez-Huelamo M, Jiménez-Gámez E, Hermo MP, et al. Determination of penicillins in milk using LC-UV, LC-MS and LC-MS/MS[J]. J Sep Sci, 2009, 32(14): 2385-2393.
¡¡¡¡[28] Shimoyama R, Ohkubo T, Sugawara K. Monitoring of carbamazepine and carbamazepine 10,11-epoxide in breast milk and plasma by high-performance liquid chromatography[J]. Ann Clin Biochem, 2000, 37 ( Pt 2): 210-215.
¡¡¡¡[29] Ghoraba Z, Aibaghi B, Soleymanpour A. Application of cation-modified sulfur nanoparticles as an efficient sorbent for separation and preconcentration of carbamazepine in biological and pharmaceutical samples prior to its determination by high-performance liquid chromatography[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2017, 1063: 245-252
¡¡¡¡[30] Padró JM, Pellegrino Vidal RB, Echevarria RN, et al. Development of an ionic-liquid-based dispersive liquid-liquid microextraction method for the determination of antichagasic drugs in human breast milk: Optimization by central composite design[J]. J Sep Sci, 2015, 38(9): 1591-1600.
¡¡¡¡[31] Lopes BR, Barreiro JC, Baraldi PT, et al. Quantification of carbamazepine and its active metabolite by direct injection of human milk serum using liquid chromatography tandem ion trap mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2012, 889-890: 17-23.
¡¡¡¡[32] Delaby C, Gabelle A, Meynier P, et al. Development and validation of dried matrix spot sampling for the quantitative determination of amyloid β peptides in cerebrospinal fluid[J]. Clin Chem Lab Med, 2014, 52(5): 649-655.
¡¡¡¡[33] Waitt C, Diliiy Penchala S, Olagunju A, et al. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2017, 1060: 300-307.
¡¡¡¡[34] Olagunju A, Amara A, Waitt C, et al. Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots[J]. J Antimicrob Chemother, 2015, 70(10): 2816-2822.
¡¡¡¡[35] Olagunju A, Bolaji OO, Amara A, et al. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS[J]. J Antimicrob Chemother, 2015, 70(2): 555-561.
¡¡¡¡[36] Raysyan A, Galvidis IA, Schneider RJ, et al. Development of a latex particles-based lateral flow immunoassay for group determination of macrolide antibiotics in breast milk[J]. J Pharm Biomed Anal, 2020, 189: 113450.
¡¡¡¡[37] Zong L, Jiao Y, Guo X, et al. Paper-based fluorescent immunoassay for highly sensitive and selective detection of norfloxacin in milk at picogram level[J]. Talanta, 2019, 195: 333-338.
¡¡¡¡[38] Sagirli O, Demirci S, ?nal A. A very simple high-performance liquid chromatographic method with fluorescence detection for the determination of gemifloxacin in human breast milk[J]. Luminescence, 2015, 30(8): 1326-1329.
¡¡¡¡[39] Salazar FR, D'Avila FB, de Oliveira MH, et al. Development and validation of a bioanalytical method for five antidepressants in human milk by LC-MS[J]. J Pharm Biomed Anal, 2016, 129: 502-508.
¡¡¡¡[40] Phyo Lwin EM, Gerber C, Song Y, et al. A new LC-MS/MS bioanalytical method for atenolol in human plasma and milk[J]. Bioanalysis, 2017, 9(7): 517-530.
¡¡¡¡[41] Lopes BR, Cassiano NM, Carvalho DM, et al. Simultaneous quantification of fluoxetine and norfluoxetine in colostrum and mature human milk using a 2-dimensional liquid chromatography-tandem mass spectrometry system[J]. J Pharm Biomed Anal, 2018, 150: 362-367.
¡¡¡¡[42] Dei Cas M, Casagni E, Gambaro V, et al. Determination of daptomycin in human plasma and breast milk by UPLC/MS-MS[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2019, 1116: 38-43.
¡¡¡¡[43] Ramírez-Ramírez A, Sánchez-Serrano E, Loaiza-Flores G, et al. Simultaneous quantification of four antiretroviral drugs in breast milk samples from HIV-positive women by an ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method[J]. Plos One, 2018, 13(1): e0191236.
¡¡¡¡[44] Manohar M, Marzinke MA. Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk[J]. Clin Biochem, 2020, 82: 66-72.
¡¡¡¡[45] Tekkeli SEK, Gazioglu I, Kiziltas MV. An HPLC Method for the Determination of Moxifloxacin in Breast Milk by Fluorimetric Detection with Precolumn Derivatization[J]. Acta Chromatographica, 2017, 29(1): 57-65.
¡¡¡¡[46] Nakamichi T, Yawata A, Hojo H, et al. Monitoring of methylergometrine in human breast milk by solid-phase extraction and high-performance liquid chromatography with fluorimetric detection[J]. Pharmazie, 2012, 67(6): 482-484.
¡¡¡¡[47] García-Gómez D, García-Hernández M, Rodríguez-Gonzalo E, et al. A fast and reliable method for the quantitative determination of benzimidazoles and metabolites in milk by LC-MS/MS with on-line sample treatment[J]. Anal Bioanal Chem, 2012, 404(10): 2909-2914.
¡¡¡¡[48] Olagunju A, Amara A, Waitt C, t al. Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots[J]. J Antimicrob Chemother, 2015, 70(10): 2816-2822.
¡¡¡¡[49] Tian H, Zhou X, Chen C, et al. Simultaneous Determination of Phenobarbital, Pentobarbital, Amobarbital and Secobarbital in Raw Milk via Liquid Chromatography with Electron Spray Ionization Tandem Mass Spectrometry[J]. Korean J Food Sci Anim Resour, 2017, 37(6): 847-854.
¡¡¡¡[50] Waitt C, Diliiy Penchala S, Olagunju A, et al. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2017, 1060: 300-307.
¡¡¡¡[51] Zhao Y, Couchman L, Kipper K, et al. A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2020, 1144: 122095.
¡¡¡¡[52] Wollein U, Schech B, Hardt J, et al. Determination and quantitation of sildenafil and its major metabolite in the breast milk of a lactating woman[J]. J Pharm Biomed Anal, 2016, 120: 100-105.
¡¡¡¡[53] Lachat L, Glauser G. Development and Validation of an Ultra-Sensitive UHPLC-MS/MS Method for Neonicotinoid Analysis in Milk[J]. J Agric Food Chem, 2018, 66(32): 8639-8646.
¡¡¡¡[54] van Pamel E, Daeseleire E. A multiresidue liquid chromatographic/tandem mass spectrometric method for the detection and quantitation of 15 nonsteroidal anti-inflammatory drugs (NSAIDs) in bovine meat and milk[J]. Anal Bioanal Chem, 2015, 407(15): 4485-4494.
¡¡¡¡[55] Ma L, Fan X, Jia L, et al. Multiresidue analysis of glucocorticoids in milk by LC-MS/MS with low-temperature purification and dispersive solid-phase extraction[J]. J Sep Sci, 2017, 40(13): 2759-2768.
¡¡¡¡[56] Desmarchelier A, Anizan S, Minh Tien M, et al. Determination of five tetracyclines and their epimers by LC-MS/MS based on a liquid-liquid extraction with low temperature partitioning[J]. Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2018, 35(4): 686-694.
¡¡¡¡[57] Dowling G, Malone E, Harbison T, et al. Analytical strategy for the determination of non-steroidal anti-inflammatory drugs in plasma and improved analytical strategy for the determination of authorized and non-authorized non-steroidal anti-inflammatory drugs in milk by LC-MS/MS[J]. Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2010, 27(7): 962-982.
¡¡¡¡[58] Gill BD, Indyk HE, Kobayashi T, et al. Comparison of LC-MS/MS and Enzymatic Methods for the Determination of Total Choline and Total Carnitine in Infant Formula and Milk Products[J]. J AOAC Int, 2020, 103(5): 1293-1300.
¡¡¡¡[59] López-García E, Mastroianni N, Postigo C, et al. Simultaneous LC-MS/MS determination of 40 legal and illegal psychoactive drugs in breast and bovine milk[J]. Food Chem, 2018, 245: 159-167.
¡¡¡¡[60] Lwin EMP, Gerber C, Song Y, et al. A new LC-MS/MS bioanalytical method for perindopril and perindoprilat in human plasma and milk[J]. Anal Bioanal Chem, 2017, 409(26): 6141-6148.

×÷Õßµ¥Î»£º»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ¸½Êôͬ¼ÃҽԺҩѧ²¿ ÏÌÄþÊÐÖÐÐÄÒ½Ôººþ±±¿Æ¼¼Ñ§Ôº¸½ÊôµÚһҽԺҩѧ²¿
Ô­Îijö´¦£ºÀîÄþºì,ÕÔæûÛ,ÇÇÈï,¶Å¹â,¹±Ñ©ÆM. ÈéÖ­ÖÐÒ©ÎïŨ¶È²â¶¨µÄÑо¿½øÕ¹[J]. ÖйúҽԺҩѧÔÓÖ¾,,:1-9.
Ïà¹ØÄÚÈÝÍƼö
Ïà¹Ø±êÇ©£º
·µ»Ø£ºÒ©ÀíѧÂÛÎÄ